WHO Reporting System for Lung Cytopathology: Insights Into the Insufficient/Inadequate/Non-Diagnostic, Atypical and Suspicious for Malignancy Categories and How to Use Them.

Advanced Search

Zahra Maleki, Sule Canberk, Andrew Field

Author Information

Zahra Maleki: Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, USA. ORCID
Sule Canberk: IPATIMUP/Instituto de Investigação e Inovação Em Saúde (i3S), University of Porto, Porto, Portugal.
Andrew Field: St Vincent's Hospital, University of NSW Sydney and Notre Dame University Sydney Medical Schools, Sydney, Australia.

PMID: 40143519 DOI: 10.1111/cyt.13479

The World Health Organization Reporting System for Lung Cytopathology (WHO System) is an international effort aiming to serve patients worldwide in all medical resource settings and improve patient care globally. It is an evidence-based standardised reporting system applicable to all respiratory cytopathology specimens. The WHO System consists of five diagnostic categories including Insufficient/Inadequate/Non-diagnostic, Benign, Atypical, Suspicious for Malignancy and Malignant. Each category has an associated risk of Malignancy established from the current literature and recommendations for further management to establish as precise a diagnosis as possible. The key diagnostic cytopathological criteria for each entity are established, a differential diagnosis based on cytopathological features that is globally applicable is discussed, and best practices in appropriate ancillary studies are presented. The Insufficient/Inadequate/Non-diagnostic, Atypical and Suspicious for Malignancy are diagnostic categories that are particularly challenging for cytopathologists and clinicians and patients due to the organ's diversity in sampling methods, cell types and the wide variety of neoplasms. Herein, we have reviewed the role of these three categories, discussed their definitions and cytopathological criteria, appropriate applications, risk of Malignancy, clinical recommendations for patient's further diagnostic workup and application of ancillary studies. The aim was to increase cytopathologists and clinicians understanding of the three categories and provide a framework for the essential discussions that should follow.

Atypical FNAB Insufficient/Inadequate/Non‐diagnostic Suspicious for malignancy WHO reporting system exfoliative lung cytopathology

W. D. Travis, E. Brambilla, M. Noguchi, et al., “Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification,” Archives of Pathology & Laboratory Medicine 137, no. 5 (2013): 668–684, https://doi.org/10.5858/arpa.2012‐0263‐RA.
L. M. Rooper, O. Nikolskaia, J. Carter, Y. Ning, M. T. Lin, and Z. Maleki, “A Single EBUS‐TBNA Procedure Can Support a Large Panel of Immunohistochemical Stains, Specific Diagnostic Subtyping, and Multiple Gene Analyses in the Majority of Non‐Small Cell Lung Cancer Cases,” Human Pathology 51 (2016): 139–145.
E. F. Rodriguez, R. Pastorello, L. Osmani, et al., “Ultrasound‐Guided Transthoracic Fine‐Needle Aspiration: A Reliable Tool in Diagnosis and Molecular Profiling of Lung Masses,” Acta Cytologica 64, no. 3 (2020): 208–215.
Papanicolaou Society of Cytopathology Task Force on Standards of Practice, “Guidelines of the Papanicolaou Society of Cytopathology for the Examination of Cytologic Specimens Obtained From the Respiratory Tract,” Diagnostic Cytopathology 21, no. 1 (1999): 61–69.
L. J. Layfield, “The Papanicolaou Society of Cytopathology Classification for Pulmonary Specimens: An Overview,” Cytopathology 27, no. 3 (2016): 149–152.
L. J. Layfield, Z. Baloch, T. Elsheikh, et al., “Standardized Terminology and Nomenclature for Respiratory Cytology: The Papanicolaou Society of Cytopathology Guidelines,” Diagnostic Cytopathology 44, no. 5 (2016): 399–409, https://doi.org/10.1002/dc.23457.
L. J. Layfield and M. Esebua, “A Modified Papanicolaou Society of Cytopathology System for Reporting Respiratory Cytology Specimens: Implications for Estimates of Malignancy Risk and Diagnostic Accuracy,” Diagnostic Cytopathology 49, no. 11 (2021): 1167–1172.
K. Hiroshima, A. Yoshizawa, A. Takenaka, et al., “Cytology Reporting System for Lung Cancer From the Japan Lung Cancer Society and Japanese Society of Clinical Cytology: An Interobserver Reproducibility Study and Risk of Malignancy Evaluation on Cytology Specimens,” Acta Cytologica 64, no. 5 (2020): 452–462.
S. Canberk, A. Field, L. Bubendorf, et al., “A Brief Review of the WHO Reporting System for Lung Cytopathology,” Journal of the American Society of Cytopathology 12, no. 4 (2023): 251–257.
A. S. Field, M. Pitman, I. A. Cree, et al., “The Rationale for the Development and Publication of the World Health Organization Reporting Systems for Cytopathology and a Brief Overview of the First Editions of the Lung and Pancreaticobiliary Systems,” Cancer Cytopathology 131, no. 12 (2023): 751–761.
WHO Reporting System for Lung Cytopathology, IAC‐IARC‐WHO Cytopathology Reporting Systems, vol. 1, 1st ed. (IAC‐IARC‐WHO Joint Editorial Board, 2022).
R. Luis, B. Thirunavukkarasu, D. Jain, and S. Canberk, “Welcoming the New, Revisiting the Old: A Brief Glance at Cytopathology Reporting Systems for Lung, Pancreas, and Thyroid,” Journal of Pathology and Translational Medicine 58, no. 4 (2024): 165–173.
F. C. Schmitt, L. Bubendorf, S. Canberk, et al., “The World Health Organization Reporting System for Lung Cytopathology,” Acta Cytologica 67, no. 1 (2023): 80–91.
D. Dolezal, I. Kholova, and G. Cai, “The World Health Organization Reporting System for Lung Cytopathology—A Review of the First Edition,” Journal of Clinical and Translational Pathology 4, no. 1 (2024): 18–35.
L. J. Layfield, T. Zhang, M. Esebua, and R. L. Schmidt, “Atypia in Pulmonary Cytology: A Cytomorphometric Analysis of the Spectrum of Changes Between Benign and Malignant,” Diagnostic Cytopathology 49, no. 8 (2021): 909–914.
L. J. Layfield, “Grey Zones in Respiratory Cytology: Atypical or Suspicious for Malignancy and Neoplasms of Unknown Malignant Potential,” CytoJournal 20 (2023): 42.
S. Canberk, D. Montezuma, O. Aydın, et al., “The New Guidelines of Papanicolaou Society of Cytopathology for Respiratory Specimens: Assessment of Risk of Malignancy and Diagnostic Yield in Different Cytological Modalities,” Diagnostic Cytopathology 46, no. 9 (2018): 725–729.
S. Canberk, V. Tischler, and M. Engels, “Current Topics and Practical Considerations of Cytology Practice in Lung Cancer: Reflexions From the Lung Symposium at the 42nd European Congress of Cytology, Malmo, 2019,” Acta Cytologica 64, no. 5 (2020): 463–470.
A. Vuorisalo, H. Huhtala, T. Paavonen, and I. Kholová, “Insufficient Endobronchial Ultrasound‐Guided Transbronchial Needle Aspiration Specimens. When and Why? The Analysis of Criteria and Reasons Behind the Insufficient Specimens,” Diagnostic Cytopathology 52, no. 5 (2024): 271–287.
L. J. Layfield and Z. Baloch, “Atypia in Pulmonary Cytology: Morphologic Spectrum and Causes,” Diagnostic Cytopathology 50, no. 4 (2022): 164–171.
I. P. Nikas, R. Souza da Silva, B. Sousa‐Pinto, and F. Schmitt, “Challenging the Concept of “Risk of Malignancy” in Cytology,” Cancer Cytopathology 132, no. 6 (2024): 335–339.
L. J. Layfield, L. Dodd, and B. Witt, “Malignancy Risk for the Categories: Non‐Diagnostic, Benign, Atypical, Suspicious, and Malignant Used in the Categorization of Endobronchial Ultrasound Guided‐Fine Needle Aspirates of Pulmonary Nodules,” Diagnostic Cytopathology 43, no. 11 (2015): 892–896.
W. A. Lai and C. C. Chen, “Evaluating the Risk of Malignancies of the Diagnostic Categories Proposed by the World Health Organization System for Reporting Lung Cytopathology: A 2‐Year Single Institutional Experience,” Acta Cytologica 68, no. 4 (2024): 351–358.
G. da Cunha Santos, M. A. Saieg, G. Troncone, and P. Zeppa, “Cytological Preparations for Molecular Analysis: A Review of Technical Procedures, Advantages and Limitations for Referring Samples for Testing,” Cytopathology 29, no. 2 (2018): 125–132.
J. S. Nigam, J. N. Bharti, A. Rath, and I. Pradeep, “A Comprehensive Review of the Newest World Health Organization (WHO) Cytopathology Reporting Systems,” Advances in Anatomic Pathology 30 (2023): 301–306.
D. Jain, T. C. Allen, D. L. Aisner, et al., “Rapid on‐Site Evaluation of Endobronchial Ultrasound‐Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society,” Archives of Pathology & Laboratory Medicine 142, no. 2 (2018): 253–262.
V. Shakthivel, C. Ahluwalia, S. Ahuja, and S. Ranga, “Diagnostic Accuracy of the WHO System for Reporting Lung Cytopathology: A Retrospective Analysis,” Diagnostic Cytopathology 53 (2025): 27–34.
L. J. Layfield, M. Esebua, L. Dodd, T. Giorgadze, and R. L. Schmidt, “The Papanicolaou Society of Cytopathology Guidelines for Respiratory Cytology: Reproducibility of Categories Among Observers,” CytoJournal 15 (2018): 22.

Journal Article Review

No available data.

OpenLB
Open Library of Bioscience